Nanoscope to Present Long-Term Data for MCO-010 in RP at Euretina and Retina Society 2025
Nanoscope Therapeutics announced it will present new long-term data from its RESTORE follow-up study, REMAIN, at two major international meetings: the 2025 Euretina Congress in Paris and the 2025 Retina Society Annual Scientific Meeting in Chicago.
The presentations will highlight positive 152-week efficacy and safety results for MCO-010 (sonpiretigene isteparvovec), Nanoscope’s lead optogenetic therapy for retinitis pigmentosa (RP). MCO-010 is administered as a one-time, in-office intravitreal injection and is the first and only therapy in a randomized, controlled trial shown to restore vision in RP patients with severe vision loss.
“Durable efficacy and long-term tolerability are meaningful for patients suffering from irreversible, progressive vision loss due to RP, and underscore the potential of MCO-010 to redefine the standard of care for these patients,” said Samarendra Mohanty, PhD, President and Chief Scientific Officer, Nanoscope. “It is an exciting time at Nanoscope as we prepare MCO-010 for commercialization, kicked off by the recent initiation of our rolling BLA with the FDA.”
The 152-week REMAIN data extend findings from the pivotal RESTORE study, reinforcing the long-term benefit and safety profile of optogenetic therapy in RP, a disease with no currently approved restorative treatments.
Presentation Details
2025 Euretina Congress — Paris, France
Title: REMAIN: 152-Week Extended Analysis From the RESTORE Study of MCO-010 Optogenetic Therapy for Retinitis Pigmentosa
Session: Free Paper 11 – Inherited Retinal Diseases
Date/Time: Friday, September 5 at 5:24 pm CET
Presenter: Jordi Monés, MD, PhD; Director, Institut de la Màcula, Barcelona, Spain
2025 Retina Society Annual Meeting — Chicago, Illinois, USA
Title: REMAIN: 152-Week Extended Analysis from the MCO-010 Optogenetic Therapy for Retinitis Pigmentosa RESTORE Study
Session: Genetic Diseases, Dystrophies, Degenerations
Date/Time: Wednesday, September 10 at 3:44 pm CDT
Presenter: Christine Kay, MD; Vitreoretinal Associates, Director of Clinical Research and Retinal Genetics